摘要
目的：探讨戈舍瑞林联合依西美坦治疗绝经前及围绝经期复发转移性乳腺癌的疗效及毒副作用。方法选择我科2008-2012年采用戈舍瑞林联合依西美坦治疗绝经前及围绝经期激素受体阳性的复发转移性乳腺癌患者20例。戈舍瑞林3．6 mg皮下注射,4周1次；依西美坦25 mg,1次/d口服。研究终点为：临床缓解（ CB）、客观缓解率（ ORR）、无进展生存期（ PFS）、总生存（ OS）和毒性反应。结果1例患者达到CR,5例患者达到PR,9例患者达到SD,其中6例SD≥6个月,5例患者达到PD。中位PFS为12．3个月（3~62个月）,中位OS为40个月（3~72个月）。 ORR为30%,CB为60%。戈舍瑞林联合依西美坦及作为一线解救治疗的PFS高于作为二线解救治疗（P=0．012）。无内脏转移患者的PFS高于内脏转移的患者（P=0．025）,未观察到严重的不良反应。结论戈舍瑞林联合依西美坦治疗绝经前及围绝经期复发转移性乳腺癌的疗效确切,耐受性良好,可以作为绝经前及围绝经期复发转移性乳腺癌内分泌治疗的理想选择。
Objective To investigate the efficacy and safety of goserelin combined with exemestane in the treatment of advanced premenopausal and perimenopausal breast cancer patients with hormone-receptor-positive. Meth-ods Twenty patients received goserelin 3. 6 mg by subcutaneous injection every 4 weeks with exemestane 25 mg daily by oral as the first-line and second-line endocrine therapy. The study endpoints were clinical benefit（ CB） ,objective re-sponse rate（ ORR） ,progression-free survival（ PFS） ,overall survival（ OS） and toxicity. Results One patient got com-plete remission（ CR） ,six patients got partial remissions（ PR） ,nine patients got stable diseases（ SD） ,six stable diseases lasted for more than six months,and six patients got progressive diseases（ PD） ,ORR was 30%,and CB was 60%,the median PFS was 12. 3（3~62）months,the median OS was 40（3~66）months. PFS of patients with first-line endocrine therapy was significantly longer than those with second-line endocrine therapy（P=0. 012）. PFS of patients with none-visceral metastasis were longer than those with visceral metastasis（P=0. 025）,no serious toxicities was observed. Con-clusion Combined therapy of goserelin and exemestane appears to be effective and well-tolerated in premenopausal and perimenopausal patients with advanced or metastasis breast cancer.
出处
《实用药物与临床》
CAS
2014年第11期1435-1439,共5页
Practical Pharmacy and Clinical Remedies
